Tower Research Capital LLC TRC Sells 309 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Tower Research Capital LLC TRC cut its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 1.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,486 shares of the biopharmaceutical company’s stock after selling 309 shares during the period. Tower Research Capital LLC TRC’s holdings in Royalty Pharma were worth $497,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Franklin Resources Inc. raised its position in shares of Royalty Pharma by 5.0% during the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after buying an additional 70,130 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock valued at $79,888,000 after purchasing an additional 130,025 shares during the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Royalty Pharma in the 4th quarter worth approximately $2,355,000. Jupiter Asset Management Ltd. acquired a new position in Royalty Pharma in the fourth quarter worth $4,950,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Royalty Pharma by 303.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company’s stock worth $13,926,000 after buying an additional 406,123 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Up 0.5 %

NASDAQ RPRX opened at $32.71 on Wednesday. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock’s 50 day moving average price is $32.51 and its two-hundred day moving average price is $29.50. The stock has a market capitalization of $18.86 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 2.31 and a beta of 0.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, May 16th. Royalty Pharma’s payout ratio is currently 60.69%.

Analyst Ratings Changes

Separately, Citigroup reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.